Late-onset malignancies according to treatment groups
| Treatment . | Type of late-occurring malignancy; patients, n (%) . | |||||
|---|---|---|---|---|---|---|
| Group . | Patients, n . | DLBCL . | AML/ALL . | MDS . | Solid tumors . | All malignancies . |
| Rituximab plus fludarabine (follow-up of prospective trial) | 29 | 2 (7) | 2 (7) | 1 (3.5) | 4 (14) | 9 (31) |
| Rituximab plus bendamustine (follow-up of prospective trial) | 45 | 2 (4.5) | 0 (0) | 0 (0) | 2 (4.5) | 4 (9) |
| All patients | 232 | 8 (3.5) | 2 (1) | 2 (1) | 18 (8) | 29 (13) |
| Treatment . | Type of late-occurring malignancy; patients, n (%) . | |||||
|---|---|---|---|---|---|---|
| Group . | Patients, n . | DLBCL . | AML/ALL . | MDS . | Solid tumors . | All malignancies . |
| Rituximab plus fludarabine (follow-up of prospective trial) | 29 | 2 (7) | 2 (7) | 1 (3.5) | 4 (14) | 9 (31) |
| Rituximab plus bendamustine (follow-up of prospective trial) | 45 | 2 (4.5) | 0 (0) | 0 (0) | 2 (4.5) | 4 (9) |
| All patients | 232 | 8 (3.5) | 2 (1) | 2 (1) | 18 (8) | 29 (13) |
ALL, acute lymphoblastic leukemia.